Welcome to our dedicated page for Ibio news (Ticker: IBIO), a resource for investors and traders seeking the latest updates and insights on Ibio stock.
iBio, Inc. (NASDAQ: IBIO) is an AI-driven biotechnology company developing precision antibody therapies for cardiometabolic diseases, obesity, cancer and other hard-to-treat conditions. The IBIO news feed on Stock Titan aggregates company press releases and other coverage so readers can follow how the business and its preclinical pipeline are evolving over time.
Recent news highlights iBio’s focus on obesity and cardiometabolic disease, including preclinical data for its Activin E antibody candidate IBIO-610 and its long-acting anti-myostatin antibody IBIO-600. The company has reported fat-selective, GLP‑1‑synergistic weight loss in diet-induced obesity mouse models, non-human primate pharmacokinetic data suggesting extended half-life and potential for infrequent dosing, and early evidence that its programs may help preserve lean mass in combination with GLP‑1 therapies. Updates also cover presentations at scientific and investor conferences such as ObesityWeek, PEGS Europe and healthcare-focused investment conferences.
Investors tracking IBIO news will also see announcements about financings, including underwritten public offerings, warrant transactions and private placements with institutional investors, along with disclosures on how proceeds are intended to support preclinical cardiometabolic programs and other pipeline assets. Regulatory and corporate developments reported via Form 8‑K, such as Nasdaq listing compliance notices, annual meeting results and updated corporate presentations, provide additional context on governance and capital markets activity.
By following this IBIO news page, readers can monitor new preclinical data, conference participation, financing transactions and key SEC-reported events that shape iBio’s progress as a preclinical-stage, AI-enabled antibody developer.
iBio (NASDAQ:IBIO) reported its fiscal year 2025 results and corporate updates, highlighting significant progress in its cardiometabolic and obesity pipeline. The company's lead candidates include IBIO-610, an activin E-targeting antibody showing 26% fat mass reduction without lean mass loss, and IBIO-600, a long-acting anti-myostatin antibody demonstrating extended half-life and dose-dependent muscle growth.
Financial highlights include revenue of $0.4M (up $0.2M YoY), R&D expenses of $8.3M (up $3.1M), and G&A expenses of $10.7M (down $1.0M). The company strengthened its position through a $50M public offering with potential for additional $50M from warrant exercises. iBio successfully transferred to Nasdaq trading and expanded its leadership team with industry veterans.
iBio (Nasdaq: IBIO) has successfully closed its previously announced public offering, raising initial gross proceeds of $50 million. The offering included pre-funded warrants to purchase 71,540,000 shares and accompanying Series G and H warrants. If all warrants are exercised, iBio could receive an additional $50 million in gross proceeds.
The offering was led by Balyasny Asset Management with participation from several prominent investors. The proceeds will be used to advance iBio's preclinical cardiometabolic programs, including IBIO-610 and IBIO-600, through key development milestones. Leerink Partners served as the lead bookrunner, with LifeSci Capital and Oppenheimer & Co. as bookrunning managers.
The Series G warrants are linked to a Trial Initiation Milestone and will expire either 30 trading days after the milestone announcement or five years from issuance, while Series H warrants have a four-year term.iBio (Nasdaq: IBIO) has announced the pricing of a $50 million public offering of pre-funded warrants and accompanying Series G warrants. The offering includes 71,540,000 pre-funded warrants to purchase common stock and Series G warrants to purchase 35,770,000 shares, along with Series H warrants.
The combined offering price is set at $0.699 per unit, with Series G and H warrants having an exercise price of $0.70 per share. If all warrants are exercised, iBio could receive additional gross proceeds of approximately $50 million. The company plans to use the proceeds to advance its preclinical cardiometabolic programs, including IBIO-610 and IBIO-600, and fund working capital requirements.
[ "Potential total gross proceeds of up to $100 million if all warrants are exercised", "Funds will advance key preclinical cardiometabolic programs IBIO-610 and IBIO-600", "Multiple tier-1 investment banks involved in the offering including Leerink Partners as lead bookrunner" ]iBio (Nasdaq: IBIO), an AI-driven precision antibody therapies company, has announced a proposed underwritten public offering. The offering includes pre-funded warrants to purchase common stock and accompanying Series G and Series H warrants.
The company plans to use the proceeds to advance its preclinical cardiometabolic programs, including IBIO-610 (myostatin and activin A bispecific) and IBIO-600 programs, as well as other preclinical pipeline assets. Leerink Partners is leading the offering as the lead bookrunning manager, with LifeSci Capital and Oppenheimer & Co. serving as additional bookrunning managers.
iBio (NASDAQ:IBIO) has announced promising preclinical results for its novel amylin receptor agonist antibody in obesity treatment. The engineered antibody demonstrated a significant 60% reduction in acute food intake in mouse models, comparable to the 67% reduction achieved by a clinically advanced DACRA peptide.
This marks the third target from iBio's partnership with AstralBio, leveraging their AI-enabled antibody discovery platform to develop selective amylin receptor targeting treatments. The approach shows potential for both monotherapy and combination therapy with GLP-1 receptor agonists, with current amylin analogs achieving up to 22.7% weight loss in combination with semaglutide and 11.8% as monotherapy in clinical development.
iBio (NASDAQ:IBIO) has announced a conference call scheduled for June 24, 2025, at 8:30 a.m. ET to discuss its obesity and cardiometabolic disease pipeline. CEO and CSO Martin Brenner will present updates on the company's next-generation antibody medicines, including IBIO-600, their long-acting Myostatin treatment, and new preclinical data on Activin E.
The presentation will also reveal a third target in their AstralBio Collaboration. The company aims to develop targeted, longer-lasting therapies with improved tolerability and sustainable efficacy. Investors can access the webcast through iBio's website, with a replay available for approximately 60 days.
iBio (NASDAQ: IBIO) has announced promising preclinical results for its first-in-class Activin E antibody in treating obesity. In a 4-week study with obese mice, the antibody achieved a 26% reduction in fat mass while preserving muscle mass. The treatment demonstrated significant reductions in various fat deposits: 31% in subcutaneous fat and 34-37% in visceral fat depots linked to cardiometabolic disease risk.
When combined with a GLP-1 receptor agonist, the Activin E antibody showed remarkable synergy, achieving a 77% reduction in total fat mass and total weight loss of 35.3% - surpassing GLP-1 alone by 7.5%. Unlike current obesity drugs that may reduce muscle mass, iBio's approach focuses on fat-specific weight loss, potentially offering a more effective solution for obesity treatment while maintaining physical function and healthy metabolism.
iBio (IBIO) reported its fiscal Q3 2025 financial results and corporate updates. The company reported a net loss of $4.9 million ($0.49 per share) compared to $2.6 million ($0.71 per share) in Q3 2024. R&D expenses increased to $1.9 million from $0.9 million, while G&A expenses rose to $3.0 million from $2.7 million.
Key developments include: uplisting to Nasdaq, promising non-human primate data for IBIO-600 (anti-myostatin antibody), in-licensing of a first-in-class Activin E antibody from AstralBio, and raising $6.2 million through warrant inducement. Cash position stood at $5.2 million as of March 31, 2025, increasing to $10.5 million by May 1, 2025 post-warrant transaction.
iBio, an AI-driven innovator of precision antibody therapies, has secured $6.2 million through a warrant inducement transaction with institutional investors. The deal involves existing warrant holders agreeing to purchase 5,626,685 shares of common stock at a reduced price of $1.11 per share.
As part of the agreement, investors received new warrants to purchase up to 11,253,370 shares at $0.86 per share, with a five-year expiration period. The transaction is expected to close around April 30, 2025, with Chardan serving as the exclusive financial advisor.
The company plans to use the net proceeds for working capital and general corporate purposes. The new securities are being offered through a private placement and will require registration with the SEC before they can be sold in the United States.